Literature DB >> 11904392

Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice.

Orlando F Bueno1, Benjamin J Wilkins, Kevin M Tymitz, Betty J Glascock, Thomas F Kimball, John N Lorenz, Jeffery D Molkentin.   

Abstract

Calcineurin is a calcium-calmodulin-regulated, serine-threonine phosphatase that functions as a key inducer of stress responsive gene expression in multiple cell types through a direct activation of nuclear factor of activated T cells and myocyte enhancer factor 2 transcription factors. In cardiomyocytes, calcineurin signaling has been implicated in the regulation of the hypertrophic response caused by pressure overload or neuroendocrine stimulation. Three separate genes encode the catalytic subunit of calcineurin in mammalian cells, CnAalpha, CnAbeta, and CnAgamma. To evaluate the necessary function of calcineurin as a hypertrophic regulatory factor, the CnAbeta gene was disrupted in the mouse. CnAbeta-deficient mice were viable, fertile, and overtly normal well into adulthood, but displayed a 80% decrease in calcineurin enzymatic activity in the heart that was associated with a 12% reduction in basal heart size. CnAbeta-deficient mice were dramatically impaired in their ability to mount a productive hypertrophic response induced by pressure overload, angiotensin II infusion, or isoproterenol infusion. Analysis of marker genes associated with the hypertrophic response revealed a partial defect in the molecular program of hypertrophy. Collectively, these data solidify the hypothesis that calcineurin functions as a central regulator of the cardiac hypertrophic growth response in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11904392      PMCID: PMC123691          DOI: 10.1073/pnas.072647999

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Many pathways to cardiac hypertrophy.

Authors:  S F Steinberg
Journal:  J Mol Cell Cardiol       Date:  2000-08       Impact factor: 5.000

Review 2.  Calcineurin: form and function.

Authors:  F Rusnak; P Mertz
Journal:  Physiol Rev       Date:  2000-10       Impact factor: 37.312

3.  Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy.

Authors:  H W Lim; L J De Windt; L Steinberg; T Taigen; S A Witt; T R Kimball; J D Molkentin
Journal:  Circulation       Date:  2000-05-23       Impact factor: 29.690

4.  Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure.

Authors:  S Haq; G Choukroun; H Lim; K M Tymitz; F del Monte; J Gwathmey; L Grazette; A Michael; R Hajjar; T Force; J D Molkentin
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

5.  The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice.

Authors:  O F Bueno; L J De Windt; K M Tymitz; S A Witt; T R Kimball; R Klevitsky; T E Hewett; S P Jones; D J Lefer; C F Peng; R N Kitsis; J D Molkentin
Journal:  EMBO J       Date:  2000-12-01       Impact factor: 11.598

6.  An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy.

Authors:  D Fatkin; B K McConnell; J O Mudd; C Semsarian; I G Moskowitz; F J Schoen; M Giewat; C E Seidman; J G Seidman
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

Review 7.  Calcineurin and beyond: cardiac hypertrophic signaling.

Authors:  J D Molkentin
Journal:  Circ Res       Date:  2000-10-27       Impact factor: 17.367

8.  Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats.

Authors:  Y Sakata; T Masuyama; K Yamamoto; N Nishikawa; H Yamamoto; H Kondo; K Ono; K Otsu; T Kuzuya; T Miwa; H Takeda; E Miyamoto; M Hori
Journal:  Circulation       Date:  2000-10-31       Impact factor: 29.690

9.  Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways.

Authors:  L J De Windt; H W Lim; S Haq; T Force; J D Molkentin
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

10.  Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension.

Authors:  A Murat; C Pellieux; H R Brunner; T Pedrazzini
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

View more
  106 in total

1.  [Mitochondrial aldehyde dehydrogenase 2 protects against high glucose-induced injury in neonatal rat cardiomyocytes by regulating CaN-NFAT3 signaling pathway].

Authors:  Jianlu Guo; Pinfang Kang; Lei Zhu; Shuo Sun; Min Tao; Heng Zhang; Bi Tang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

Review 2.  Meeting of the minds: metalloneurochemistry.

Authors:  Shawn C Burdette; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

3.  Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy.

Authors:  Rick B Vega; Beverly A Rothermel; Carla J Weinheimer; Atilla Kovacs; R H Naseem; Rhonda Bassel-Duby; R S Williams; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-06       Impact factor: 11.205

4.  Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect.

Authors:  Leslie G Cook; Valorie L Chiasson; Cheng Long; Gang-Yi Wu; Brett M Mitchell
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

5.  NFATc1 regulates lymphatic endothelial development.

Authors:  Rishikesh M Kulkarni; James M Greenberg; Ann L Akeson
Journal:  Mech Dev       Date:  2009-02-20       Impact factor: 1.882

6.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex.

Authors:  Hui-Hua Li; Vishram Kedar; Chunlian Zhang; Holly McDonough; Ranjana Arya; Da-Zhi Wang; Cam Patterson
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

7.  Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop.

Authors:  Hyun Kook; John J Lepore; Aaron D Gitler; Min Min Lu; Wendy Wing-Man Yung; Joel Mackay; Rong Zhou; Victor Ferrari; Peter Gruber; Jonathan A Epstein
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

8.  c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling.

Authors:  Qiangrong Liang; Orlando F Bueno; Benjamin J Wilkins; Chia-Yi Kuan; Ying Xia; Jeffery D Molkentin
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

9.  Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.

Authors:  Cameron Donaldson; Sarah Eder; Corey Baker; Mark J Aronovitz; Alexandra Dabreo Weiss; Monica Hall-Porter; Feng Wang; Adam Ackerman; Richard H Karas; Jeffery D Molkentin; Richard D Patten
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

10.  The scaffold protein muscle A-kinase anchoring protein β orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure.

Authors:  Michael D Kritzer; Jinliang Li; Catherine L Passariello; Marjorie Gayanilo; Hrishikesh Thakur; Joseph Dayan; Kimberly Dodge-Kafka; Michael S Kapiloff
Journal:  Circ Heart Fail       Date:  2014-05-08       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.